Smoking and EGFR status may predict outcomes of advanced NSCLC treated with PD‐(L)1 inhibitors beyond first line: A meta‐analysis
- 8 November 2017
- journal article
- research article
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 12 (5) , 1809-1819
Abstract
Objectives: The aim of this study was to assess the potential clinical and biological predictive markers of survival in pretreated advanced NSCLC patients treated with the three PD‐(L)1 inhibitors (nivolumab, pembrolizumab and atezolizumab).Data source/study selection: PubMed database has been searched. The review author extracted relevant information on participant characteristics and study outcomes for this review and assessed risk of bias of the included trials. Data analysis was conducted through RevMan v.5.3.Main results: Five randomized controlled trials with 3013 patients were included. There was no predictive value for the age of the patients (taking 65 years as a cutoff value), the histology (squamous vs nonsquamous) or performance score (score 0 vs score 1); while there appears to be a value for smoking history and EGFR status. The pooled HR for death for patients with EGFR mutant disease was 1.11 [95% CI: 0.80, 1.53; P = 0.54]; while pooled HR for death for patients with EGFR wild type disease was 0.67 [95% CI: 0.60, 0.75; P < 0.00001]. The pooled HR for death for patients with current/former smokers was 0.71 [95% CI: 0.63, 0.82; P < 0.00001]; while pooled HR for death for patients with never smokers was 0.79 [95% CI: 0.60, 1.06; P = 0.11]. However, because of the low‐to‐moderate quality of data, these conclusions may change with publication of other ongoing trials.Conclusions: Smoking history and EGFR status may help predict the performance of PD‐(L)1 inhibitors vs docetaxel in previously treated NSCLC patients.Keywords
This publication has 27 references indexed in Scilit:
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015
- Risk of Fatal Pulmonary Events in Patients with Advanced Non-Small-Cell Lung Cancer Treated with EGF Receptor Tyrosine Kinase Inhibitors: A Comparative Meta-AnalysisFuture Oncology, 2015
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialThe Lancet Oncology, 2015
- Methods for Staging Non-small Cell Lung CancerChest, 2013
- At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapyJournal of Leukocyte Biology, 2013
- Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient dataThe Lancet, 2010
- Lung Cancer Occurrence in Never-Smokers: An Analysis of 13 Cohorts and 22 Cancer Registry StudiesPLOS Medicine, 2008
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986